Kesmalea

Targeted protein degradation is a promising therapeutic approach, but most degrader molecules are too large to cross the blood-brain barrier – a critical challenge for treating neurological conditions.

Kesmalea is working to change that. Its SELFTAC® platform creates smaller, smarter molecules that can cross into the brain and target hard-to-reach diseases like cancer and neurological disorders. By overcoming the size limits of older drugs, Kesmalea’s approach opens the door to powerful new treatments for patients with limited options today.